Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
881 stopped studies mapped to Malignant Intestinal Neoplasm and descendants · 90% state a reason
Over the 881 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04856787 | A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the… | Phase 2 / Phase 3 | terminated | Apr 23, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Adjustment of the Company's R\&D Strategy | Sponsor / business decision |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Phase 3 | terminated | Jun 10, 2015 | Swiss Cancer Institute | Board decision in 2020 due to lack of financial funding. | Funding |
| NCT03879811 | Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal… | Phase 2 | withdrawn | Mar 19, 2019 | Memorial Sloan Kettering Cancer Center | No accrual | Enrollment / accrual |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT01550510 | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for… | Phase 1 / Phase 2 | terminated | Mar 12, 2012 | Thomas Jefferson University | Closed: low enrollment, many treatment options available for Colorectal Cancer | Enrollment / accrual |
| NCT04853043 | Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic…(APK Mutant) | Phase 2 | terminated | Apr 21, 2021 | University of Utah | PI Determination - Slow recruitment, funding concerns, poor response to treatment | Enrollment / accrual |
| NCT05251233 | Role of Proton Pump Inhibitors on the Postoperative Course Following… | Phase 2 | terminated | Feb 22, 2022 | Washington University School of Medicine | Investigator and study team chose to end study early. | Investigator |
| NCT06194877 | A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With… | Phase 1 | terminated | Jan 8, 2024 | MapKure, LLC | Funding terminated due to business reasons | Funding |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | Phase 1 | withdrawn | Jul 11, 2023 | Orion Biotechnology Polska Sp. z o.o. | study terminated due to changes in the drug development plan | Other (stated, no rule matched) |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT04450836 | Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic…(SOREGATT) | Phase 2 | terminated | Jun 30, 2020 | UNICANCER | Following the presentation of the SUNLIGHT study results at ASCO GI and the rapid change in patient… | Other (stated, no rule matched) |
| NCT04108481 | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer(iRE-C) | Phase 1 | terminated | Sep 30, 2019 | University of Iowa | DSMC-directed closure | Other (stated, no rule matched) |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT05375708 | Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with…(SIRIUS) | Phase 2 | suspended | May 17, 2022 | UMC Utrecht | Pilot study findings pointed to a overhaul in study design | Other (stated, no rule matched) |
| NCT01372696 | Endoscopic Characteristics of Colonic Tumours(C-LST) | N/A | withdrawn | Jun 14, 2011 | Professor Michael Bourke | study abandoned | Other (stated, no rule matched) |
| NCT04952753 | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy…(daNIS-3) | Phase 2 | terminated | Jul 7, 2021 | Novartis Pharmaceuticals | The study was terminated early due to the halt of NIS793 treatment and urgent safety measures… | Safety / toxicity |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT05179837 | Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal… | N/A | terminated | Jan 5, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jul 26, 2021 | Tarus Therapeutics, Inc. | Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6).… | Other (stated, no rule matched) |
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | Phase 3 | terminated | Mar 20, 2020 | Peter MacCallum Cancer Centre, Australia | Not meeting recruitment timelines | Enrollment / accrual |
| NCT05446129 | A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in… | Phase 1 | terminated | Jul 6, 2022 | Boehringer Ingelheim | Company decision | Sponsor / business decision |
| NCT05584540 | UNTIRE: Cancer-related Fatigue With Digital Treatment | N/A | withdrawn | Oct 18, 2022 | Dana-Farber Cancer Institute | loss of funding | Funding |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04406857 | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy… | Phase 1 | terminated | May 29, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03169777 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects… | Phase 1 / Phase 2 | withdrawn | May 30, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid… | Phase 1 | terminated | Jun 18, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT00961571 | Sunitinib and Capecitabine for First Line Colon Cancer | Phase 2 | terminated | Aug 19, 2009 | Georgetown University | Unanticipated side effects and futility | Efficacy / futility |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small… | Phase 1 | terminated | Nov 30, 2022 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT05158374 | Molecular Effects of Aspirin & Metformin on Colonic Epithelium | N/A | withdrawn | Dec 15, 2021 | University of Edinburgh | withdrawn prior to gaining approvals | Other (stated, no rule matched) |
| NCT03117972 | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and…(CLavSyn) | Phase 2 | terminated | Apr 18, 2017 | Centre Hospitalier Universitaire de Besancon | enrollment too slow | Enrollment / accrual |
| NCT03764137 | Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer(Panitumumab) | Phase 1 / Phase 2 | withdrawn | Dec 4, 2018 | University of Alabama at Birmingham | Study was not able to enroll any subjects | Enrollment / accrual |
| NCT04916236 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers(SHERPA) | Phase 1 | terminated | Jun 7, 2021 | The Netherlands Cancer Institute | Due to a lack of safety and efficacy. | Safety / toxicity |
| NCT01167725 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With… | Phase 3 | terminated | Jul 22, 2010 | Alliance for Clinical Trials in Oncology | not stated | Not stated |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT05281276 | Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) | Phase 1 | terminated | Mar 16, 2022 | Taipei Medical University Shuang Ho Hospital | The overall profile does not support development for metastatic colorectal cancer | Other (stated, no rule matched) |
| NCT04975256 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Phase 1 | terminated | Jul 23, 2021 | Mirati Therapeutics Inc. | The decision was made to terminate this study to further enrollment, as of 08 March 2022. The… | Enrollment / accrual |
| NCT04093557 | Improving Outpatient Colonoscopy Bowel Prep With the Orton Score | N/A | withdrawn | Sep 18, 2019 | University of Virginia | Not enough funding for research coordinator. | Funding |
| NCT03802747 | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | Phase 1 | withdrawn | Jan 14, 2019 | University of Colorado, Denver | PI left the institution | Investigator |
| NCT05164315 | Comparison Between Tailored Surgery Versus Total Mesorectal Excision in ycT2-3N0M0 | N/A | terminated | Dec 20, 2021 | Seoul National University Hospital | the high proportion of patients requiring TME(control group) suggests that proceeding with a… | Other (stated, no rule matched) |
| NCT04508140 | Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver… | Phase 2 | terminated | Aug 11, 2020 | Highlight Therapeutics | Low recruitment rate | Enrollment / accrual |
| NCT05427344 | Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer… | N/A | withdrawn | Jun 22, 2022 | Tel Aviv University | The study was stopped because we were unable to recruit participants as planned. Therefore, it was… | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT02972034 | Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With… | Phase 1 | terminated | Nov 23, 2016 | Merck Sharp & Dohme LLC | business reasons. | Sponsor / business decision |
| NCT05824559 | ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer | Phase 1 | terminated | Apr 21, 2023 | MEI Pharma, Inc. | Company decision to wind down operations, close all clinical programs and evaluate strategic options | Sponsor / business decision |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the… | Phase 2 | withdrawn | Aug 28, 2024 | City of Hope Medical Center | Abandoned 9/23/24 | Other (stated, no rule matched) |
| NCT04258111 | IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient… | Phase 2 | terminated | Feb 6, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | After careful consideration, our company has decided to revise the overall development strategy for… | Sponsor / business decision |
| NCT03228043 | Apatinib for Resectable Colorectal Cancer | N/A | withdrawn | Jul 24, 2017 | Nanchong Central Hospital | It's not possible to complete in our hospital. | Other (stated, no rule matched) |
| NCT04840186 | EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden(EXCALIBUR3) | Phase 2 | suspended | Apr 9, 2021 | Oslo University Hospital | Not enough patients | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 18, 2025source: clinicaltrials